VETO Vetoquinol SA
Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA operates as a subsidiary of Soparfin SCA.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Vetoquinol (EPA: VETO)
›
Vetoquinol (EPA: VETO) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2,526 employees.
The shares were at 86.30 EUR on 19 November 2026, up 19.4% over 52 weeks. Its 52-week range is 65.70 EUR to 91.50 EUR: the price is 5.7% below the high and 31.4% above the low.
At a market capitalisation of 1.00B EUR, it trades at 15.9 times trailing earnings and 14.8 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 36% for VETO. It pays a dividend yielding 1.08% (it pays out 17% of its earnings), against a median of 1.90% among the dividend payers in that peer group.
Vetoquinol reports return on equity of 9.7%, an operating margin of 16.0% and revenue up 0.6% year over year.
It holds more cash than debt, a net cash position of 222.85M EUR. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 92.25 EUR is 6.9% above the current price. The next earnings report is expected on 25 March 2027.